

**Question for written answer E-015833/2015  
to the Commission**  
Rule 130  
**Rolandas Paksas (EFDD)**

Subject: Availability of modern medicines

Currently, many innovative medicines registered in the EU, which are available and used in a large number of developed European countries, are not available to the residents of certain countries, including Lithuania. There is a wait of five to ten years for medicines to be reimbursable and available to sick people. This is much longer than in other Member States.

What measures does the Commission intend to take in order to ensure that seriously ill people have a level playing field as regards access to innovative medicines in all Member States?

Does the Commission intend to establish a common European strategy that would incorporate a collective bargaining process for the pharmaceutical industry, and what measures does it intend to take in the immediate future in order to improve the systems for the reimbursement of medicines?

How does the Commission intend to ensure sustainable regulation and encourage investment in new, modern medicines?